Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
BRISBANE, Calif., May 03, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced it will host a company overview webinar on Wednesday, May 10, 2017, at 1:30 p.m. ET.
Dr. Cameron Durrant, chairman and CEO, will present an update on the company, its growth initiative progress and upcoming key milestones. The webinar will feature a presentation that can be accessed via the webcast link below. A question-and-answer session will follow.
Date: Wednesday, May 10, 2017
Time: 1:30 p.m. ET (10:30 a.m. PT)
Dial-in: 1-888-267-6301
Toll/International Dial-in: 1-719-457-2734
Webcast: http://public.viavid.com/index.php?id=124313
A telephone replay will be available approximately two hours after the call through June 10, 2017. Access the replay by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 from international locations, and entering the replay pin number: 8563194.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab, for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
